Pfizer Inc. (PFE), Tuesday announced that Mikael Dolsten will step down from the role of Chief Scientific Officer, and President, Pfizer Research & Development.
The drug manufacturer also stated that Dolsten will continue to serve in his current position until a successor is appointed.
To identify a new chief scientific officer, Pfizer will initiate an external search which is expected to last through early next year.
Currently, Pfizer's stock is moving down 1.84 percent, to $ 27.42 on the New York Stock Exchange.
For comments and feedback: editorial@rttnews.com